VolitionRx (VNRX) Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for VolitionRx in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VNRX shares.
View VNRX analyst ratings or view top-rated stocks.

4 equities research analysts have issued twelve-month price objectives for VolitionRx's stock. Their VNRX share price forecasts range from $5.00 to $6.00. On average, they anticipate the company's stock price to reach $5.67 in the next year. This suggests a possible upside of 290.8% from the stock's current price.
View analysts price targets for VNRX or view top-rated stocks among Wall Street analysts.

VolitionRx's stock was trading at $1.72 on January 1st, 2023. Since then, VNRX stock has decreased by 15.7% and is now trading at $1.45.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our VNRX earnings forecast.

VolitionRx Limited (NYSEAMERICAN:VNRX) announced its quarterly earnings data on Wednesday, March, 15th. The medical research company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.15) by $0.02. The medical research company earned $0.12 million during the quarter, compared to the consensus estimate of $0.06 million. VolitionRx had a negative net margin of 9,158.31% and a negative trailing twelve-month return on equity of 15,493.47%.

Based on aggregate information from My MarketBeat watchlists, some companies that other VolitionRx investors own include Chesapeake Energy (CHKAQ), Bausch Health Companies (BHC), Verastem (VSTM), Exelixis (EXEL), Protalix BioTherapeutics (PLX), Rigel Pharmaceuticals (RIGL), CRISPR Therapeutics (CRSP), TherapeuticsMD (TXMD), ADMA Biologics (ADMA) and Bausch Health Companies (BHC).

VolitionRx trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "VNRX."

VolitionRx's stock is owned by many different retail and institutional investors. Top institutional investors include Lagoda Investment Management L.P. (5.98%), BlackRock Inc. (0.87%), Cerity Partners LLC (0.10%), Bank of America Corp DE (0.10%), JPMorgan Chase & Co. (0.06%) and Cubist Systematic Strategies LLC (0.05%). Insiders that own company stock include Cameron John Reynolds, Guy Archibald Innes, Jacob Vincent Micallef, Jason Bradley Md Terrell, Kim Nguyen, Martin Charles Faulkes, Nicholas Plummer and Salvatore Thomas Butera.
View institutional ownership trends.

Shares of VNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VNRX stock can currently be purchased for approximately $1.45.

VolitionRx (NYSEAMERICAN:VNRX) has a market capitalization of $91.61 million and generates $310,000.00 in revenue each year. The medical research company earns $-30,270,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis.

VolitionRx's mailing address is 13215 BEE CAVE PARKWAY GALLERIA OAKS B SUITE 125, AUSTIN TX, 78738. The official website for the company is www.volitionrx.com. The medical research company can be reached via phone at (646) 650-1351, via email at investorrelations@volition.com, or via fax at 65 32 8172 5651.